The lack of updated guidance for FY22 and clear confirmation of a buyout for FY23 (be patient) weighed on the share price today. For our part, we continue to see positives, particularly with regard to NGP, whose targets have been reconfirmed.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The lack of updated guidance for FY22 and clear confirmation of a buyout for FY23 (be patient) weighed on the share price today. For our part, we continue to see positives, particularly with regard to NGP, whose targets have been reconfirmed.
